Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Jardiance’s CKD Indication in Line for Japan Approval with Key Panel Nod
Nippon Boehringer Ingelheim’s SGLT2 inhibitor Jardiance (empagliflozin) on January 26 cleared the review of a key health ministry panel for an additional indication of chronic kidney disease (CKD), putting it in line for regulatory approval sometime soon. The Pharmaceutical Affairs…
To read the full story
Related Article
- Japan Approves Jardiance for CKD, Label Expansion for Opdivo and More
February 13, 2024
REGULATORY
- Briviact Set for Price Cut with CEA Adjustment Rate of 0.1
April 9, 2026
- Chuikyo Sets Reimbursement Pathways for Five Regenerative Medicine Products
April 9, 2026
- Japan OKs Listing of Exdensur, Aquipta, Tukysa, and More; New Price Rules Applied to Two
April 9, 2026
- Chuikyo Names Hosei Prof. Sugahara to Drug Pricing, CEA Panels
April 9, 2026
- MHLW Publishes Updated LLP List with Higher Surcharges from June
April 8, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…